Observational Analysis Links Goal Setting to Greater Tirzepatide Weight Loss at 12 Months

The study examined electronic records from Voy platform users starting tirzepatide, tracking 21,490 at six months and 4,429 at 12 months. Females showed higher odds of reaching the 20% threshold than males; prior structured dieting and explicit goal setting each added incremental loss. Patients with type 2 diabetes, hypertension, or MASLD were less likely to hit the target.

Because the data are observational, selection bias and unmeasured adherence differences cannot be excluded. Goal setting may proxy for higher motivation or access to behavioral support rather than exert a direct causal effect. Sex differences align with pharmacokinetic patterns seen in SURMOUNT trials but require confirmation.

For millions facing high out-of-pocket costs, a low-cost behavioral add-on that improves response could alter cost-effectiveness calculations. Payers may eventually require documented goals before continued coverage.

Next steps include an RCT randomizing goal-setting interventions alongside tirzepatide to isolate the incremental effect on retention and body weight.